Zacks: Brokerages Anticipate Motus GI Holdings Inc (NASDAQ:MOTS) Will Post Quarterly Sales of $280,000.00

Wall Street analysts expect Motus GI Holdings Inc (NASDAQ:MOTS) to report sales of $280,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Motus GI’s earnings, with the lowest sales estimate coming in at $250,000.00 and the highest estimate coming in at $300,000.00. The business is expected to report its next quarterly earnings report on Wednesday, March 25th.

On average, analysts expect that Motus GI will report full year sales of $280,000.00 for the current fiscal year, with estimates ranging from $260,000.00 to $300,000.00. For the next fiscal year, analysts forecast that the business will report sales of $8.30 million, with estimates ranging from $6.11 million to $10.50 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Motus GI.

Motus GI (NASDAQ:MOTS) last posted its quarterly earnings data on Thursday, November 14th. The company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.07.

Several equities analysts recently weighed in on MOTS shares. Dougherty & Co set a $7.00 target price on Motus GI and gave the company a “buy” rating in a research report on Thursday, September 26th. Zacks Investment Research upgraded Motus GI from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a report on Wednesday, November 20th.

In other Motus GI news, Director Gary E. Jacobs bought 17,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was acquired at an average cost of $1.54 per share, with a total value of $26,180.00. Following the completion of the purchase, the director now directly owns 9,100 shares in the company, valued at $14,014. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 18.14% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. CVI Holdings LLC purchased a new position in Motus GI in the 2nd quarter worth approximately $42,000. Northern Trust Corp bought a new stake in Motus GI in the second quarter worth $52,000. Morgan Stanley boosted its holdings in Motus GI by 1,333.3% in the second quarter. Morgan Stanley now owns 30,100 shares of the company’s stock worth $91,000 after acquiring an additional 28,000 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in Motus GI in the second quarter worth $107,000. Finally, BlackRock Inc. boosted its holdings in Motus GI by 1,004.4% in the second quarter. BlackRock Inc. now owns 69,889 shares of the company’s stock worth $212,000 after acquiring an additional 63,561 shares in the last quarter. Institutional investors and hedge funds own 43.30% of the company’s stock.

NASDAQ MOTS traded down $0.15 on Thursday, hitting $2.30. 148,151 shares of the company traded hands, compared to its average volume of 101,632. The company has a market capitalization of $70.55 million, a price-to-earnings ratio of -1.87 and a beta of 1.52. The company has a current ratio of 7.80, a quick ratio of 7.59 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average price is $1.80 and its 200-day moving average price is $2.53. Motus GI has a 52-week low of $1.43 and a 52-week high of $4.99.

About Motus GI

Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.

See Also: What are economic reports?

Get a free copy of the Zacks research report on Motus GI (MOTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Motus GI (NASDAQ:MOTS)

Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.